Edgestream Partners’s Cytokinetics CYTK Stock Holding History

Edgestream Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,491	Closed	-$1.55M	–	997
2026 Q1	$1.55M	Sell	23,491 -5,793	-20%	-$368K	0.05%	553
2025 Q4	$1.86M	Buy	+29,284	New	+$1.82M	0.05%	554
2025 Q3	–	Sell	-15,275	Closed	-$505K	–	913
2025 Q2	$505K	Sell	15,275 -2,941	-16%	-$102K	0.01%	730
2025 Q1	$732K	Buy	+18,216	New	+$837K	0.02%	652
2024 Q3	–	Sell	-15,835	Closed	-$858K	–	887
2024 Q2	$858K	Buy	+15,835	New	+$956K	0.04%	556

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edgestream Partners's CYTK Position: Q2 2026 in Review

Edgestream Partners sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 23,491 shares — an estimated $1.55M sold.

Edgestream Partners first reported a position in CYTK in Q2 2024 and held it in 5 quarters. The position peaked at $1.86M in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Edgestream Partners reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
Edgestream Partners sold 23,491 Cytokinetics shares in Q2 2026, an estimated $1.55M.
Edgestream Partners first reported a position in Cytokinetics in Q2 2024 and held it in 5 quarters.
Edgestream Partners's Cytokinetics position peaked at $1.86M in Q4 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.